A: Mounjaro is a medication used to treat type 2 diabetes. Like all medications, tirzepatide may cause side effects in some people. Some of the common side effects of tirzepatide include:

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Decreased appetite
• Headache
• Fatigue
• Dizziness

These side effects usually go away on their own as the body adjusts to the medication. However, if these side effects persist or become severe, you should contact your healthcare provider. Some less common but more serious side effects of tirzepatide may include:

• Pancreatitis (inflammation of the pancreas)
• Gallbladder disease
• Kidney problems
• Hypoglycemia (low blood sugar)
• Hypersensitivity reactions

Additional study is ongoing and looking closely for other unanticipated adverse effects. As of now, there has yet to be long-term safety data on this drug. When considering Mounjaro, it is important to remember that Mounjaro has been shown to decrease the effectiveness of oral birth control. Patients using oral hormonal contraceptives should switch to a non-oral contraceptive method before starting this medication.

A: Production and distribution of tirzepatide to pharmacies started in June 2022. The availability of the drug is limited. 

A: Tirzepatide is a “dual agonist” that activates both GLP-1 and GIP receptors and the glucagon receptor. This helps to lower blood sugar levels by increasing insulin release, slowing glucose release from the liver, and reducing glucagon release. Additionally, tirzepatide may help with weight loss by reducing appetite and promoting feelings of fullness. 

This means it can do two things:

• Stimulate GLP-1 receptors in the body to help control blood glucose and reduce hunger, promoting weight loss.
• Promote the release of a glucose-dependent insulinotropic polypeptide which helps modulate levels of a hormone called glucagon and improve insulin sensitivity of adipose (fat) tissue.

A: Yes, tirzepatide is US Food and Drug Administration (FDA) approved for weight management in addition to its use for treating type 2 diabetes. It is the first medication approved by the FDA for both purposes.

In clinical trials, tirzepatide has been shown to lead to significant weight loss in people with obesity or overweight, including those without diabetes. The exact mechanism by which tirzepatide promotes weight loss has yet to be fully understood. Still, it is thought to be related to its effects on appetite and satiety and its ability to improve glucose control.

It is important to note that tirzepatide is not a standalone weight loss medication and should only be used under the supervision of a healthcare professional. It is intended for people with a body mass index (BMI) of 27 or greater who also have a weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. Like all medications, tirzepatide may cause side effects and should be used only as directed by a healthcare professional.

A: In clinical trials, tirzepatide has been shown to be effective in promoting weight loss in people with overweight or obesity.

For example, in a 72-week study involving people with obesity, tirzepatide led to an average weight loss of 16.0% from baseline compared to 2.5% in the placebo group. In another 52-week study involving people with overweight or obesity, tirzepatide led to an average weight loss of 12.4% from baseline compared to 2.4% in the placebo group.

Tirzepatide has also been shown to be effective in helping people with type 2 diabetes to achieve both glycemic and weight goals. In a 52-week study involving people with type 2 diabetes and overweight or obese, tirzepatide led to an average weight loss of 9.5% from baseline compared to 3.1% in the placebo group.

It is important to note that the amount of weight loss achieved with tirzepatide may vary from person to person and depends on factors such as diet, exercise, and individual response to the medication. 

A: Tirzepatide is a newer medication for weight loss, so there is limited direct comparison data with other weight loss medications or weight loss surgery. However, based on the available evidence, tirzepatide appears to be a promising option for people with overweight or obesity.

In clinical trials, tirzepatide has been shown to lead to significant weight loss, with an average weight loss of 9.5% to 16.0% from baseline, depending on the study population. This weight loss is comparable to that achieved with other medications for weight loss, such as liraglutide and semaglutide, which are also GLP-1 receptor agonists. However, tirzepatide has the added benefit of activating the GIP and glucagon receptors, which may contribute to its effectiveness.

Compared to weight loss surgery, such as gastric bypass or sleeve gastrectomy, tirzepatide may not lead to as much weight loss, but it is less invasive and has fewer associated risks. Weight loss surgery can result in significant weight loss, with an average weight loss of 30% to 40% of excess body weight. Still, it carries risks like bleeding, infection, and anesthesia-related complications. If you do not currently qualify for weight loss surgery, Moujaro may he

Ultimately, the treatment choice for overweight or obesity depends on individual factors such as medical history, body mass index, and personal preferences. Healthcare providers can help determine the most appropriate treatment option for each individual based on their unique needs and goals.